Advertisement

Topics

STAT Plus: Fibrogen’s obtuse disclosures about anemia pill raise concerns over heart safety, putting approval at risk

07:52 EDT 10 May 2019 | STAT

Fibrogen “believes” that its experimental anemia pill is safe, but the drug maker refused to disclose the actual data on cardiac safety in thousands of patients in clinical trials.

Original Article: STAT Plus: Fibrogen’s obtuse disclosures about anemia pill raise concerns over heart safety, putting approval at risk

NEXT ARTICLE

More From BioPortfolio on "STAT Plus: Fibrogen’s obtuse disclosures about anemia pill raise concerns over heart safety, putting approval at risk"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...